Pieter Wesseling

Pieter Wesseling

Amsterdam, Netherland

- pathologist/neuropathologist
- full professor in neuro-oncological pathology
Radboud University Medical Center (RadboudUMC), Nijmegen, The Netherlands (2008 - 2016) and VU University Medical Center (VUMC), Amsterdam, The Netherlands (since 2012)
- present affiliations:
* Dept. of Pathology, VU University Medical Center (VUMC), Amsterdam, The Netherlands
* Diagnostic Lab, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
* Dept. of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

Training, affiliations etc:
- 1984-1991: training in Pathology & Neuropathology (incl. Neurology/Neurosurgery), RadboudUMC
- 1991-1992: fellowship Neuropathology/Neuro-oncology Dept. of Pathology, Duke University Medical Center, Durham NC, USA; supervisor Prof. Peter Burger (funded by KWF/Dutch Cancer Society & RadboudUMC)
- 1992-2016: staff member Dept. of Pathology, RadboudUMC
- 2010-present: staff member Dept. of Pathology & Professor Neuro-oncological Pathology, VUMC
- 1997: thesis “Angiogenesis in brain tumors; pathobiological and clinical aspects’; supervisors: Prof. Peter Burger (Duke University Medical Center, Durham NC, USA) and Prof. Dirk Ruiter (RadboudUMC)
- 2016 (per Sept. 1st): also affiliated with Dept. of Pathology, Princess Máxima Center/National Center for Pediatric Oncology Utrecht and University Medical Center Utrecht.

Professional experience:
- 1992 – present: author/co-author of > 250 papers in international, peer-reviewed journals (vast majority of these on neuro-oncological topics); see also below;
- 2004-2010 : personal clinical research award KWF/Dutch Cancer Society KUN 2003-2975 “Brain invasion by primary and metastatic tumors: molecular and cellular dissection of tumor-microenvironment interactions”.
- 2004 – present: coördinator (together with Prof. Kros, Rotterdam) of international course ‘Tumours of the Central Nervous System and its Coverings’ of the European Confederation of Neuropathological Societies (organized every two years)
- 2000 – present: consultant for funding organizations in e.g. Netherlands (NWO, Dutch Cancer Society, Hersenstichting), USA, Switzerland, Portugal, France, England
- 2000 – present: editorial board member of several ‘top 5’ neuropathological/neuro-oncological journals (Acta Neuropathologica; Neuro-Oncology; Brain Pathology, Neuropathology & Applied Neurobiology); frequent ad-hoc reviewer for many other peer-reviewed journals
- 1998 – present: Principle investigator of multiple research projects (mainly funded by KWF/Dutch Cancer Society); supervisor/promotor of multiple PhD students/theses
- 1999 – present: member Brain Tumor Pathology Panel, EORTC; central reviewing pathologist in several EORTC trials
- 1998 – 2006: president Dutch Society for Neuropathology
- 1992 – present: member of multiple professional organizations, incl. Dutch Society for Pathology (NVVP), Dutch Society for Neuropathology (NVvNP), American Association of Neuropathologists (AANP), International Society of Neuropathology (ISN), European Confederation of Neuropathological Societies (EURO-CNS)
- 2005 - present: co-author on multiple chapters in 4th edition (published in 2007) and updated 4th edition (published in 2016) of WHO Classification of CNS Tumours; invited participant of Consensus and Editorial Meeting for 2016 Classification (Heidelberg, June 2015)
- 2016 - present: invited member of cIMPACT-NOW (consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, i.e. aiming for advancing brain tumor classification).
- 2017 - present: invited member of ICCR (International Consortium for Cancer Reporting), neuro-oncology branch (aiming for improving integrated reporting of morphological and molecular findings in CNS tumors).

- (co-)author of over 250 articles (vast majority of these on CNS tumors) in international, peer-reviewed journals, see wesseling-p in PubMed (http://www.ncbi.nlm.nih.gov/pubmed)
- H-index (assessed in Sept. 2017 using Researcher ID): 47
- three examples of more recent papers with high scientific and/or societal impact in last three years:
1. Best MG, ..., Wesseling P, Wurdinger T. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 2015;28:666-76 (co-senior auteur of this 'ground-breaking' work on liquid biopsy approach;
2. Louis DN, Perry A, ..., Wesseling P. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24:429-35;
3. van Thuijl HF, ..., Wesseling P, Ylstra B. Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biol. 2014;15:471.